Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
134.2 USD | -0.86% | +4.45% | -2.70% |
Apr. 25 | Labcorp beats quarterly estimates on strong testing demand | RE |
Apr. 24 | Jefferies Adjusts Price Target on Quest Diagnostics to $160 From $155 | MT |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The group shows a rather high level of debt in proportion to its EBITDA.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.70% | 15.04B | A- | ||
-14.94% | 84.87B | B- | ||
+13.17% | 83.08B | C+ | ||
+10.92% | 29.4B | C+ | ||
-13.01% | 16.72B | B | ||
-3.06% | 16.4B | A- | ||
-3.97% | 11.88B | A- | ||
-1.42% | 11.88B | A- | ||
-31.75% | 11.86B | - | - | |
+27.40% | 11.64B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated